Comparative Pharmacology
Head-to-head clinical analysis: ADDERALL 20 versus ADDERALL XR 20.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADDERALL 20 versus ADDERALL XR 20.
ADDERALL 20 vs ADDERALL XR 20
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adderall 20 is a combination of amphetamine and dextroamphetamine, which are central nervous system stimulants. They increase the levels of norepinephrine and dopamine in synaptic clefts by inhibiting their reuptake and promoting their release from presynaptic neurons.
Adderall XR 20 is a combination of amphetamine enantiomers (dextroamphetamine and levoamphetamine). It increases synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and promoting their release from presynaptic terminals.
Initial: 5 mg orally once or twice daily; may increase by 5 mg increments at weekly intervals. Usual effective dose: 20-40 mg/day divided into 1-2 doses. Maximum: 40 mg/day (immediate-release); 60 mg/day (extended-release).
20 mg orally once daily in the morning.
None Documented
None Documented
d-Amphetamine: 10-13h; l-Amphetamine: 13-16h. Clinical steady-state reached in 2-3 days.
Approximately 10-13 hours for d-amphetamine and 13-15 hours for l-amphetamine in adults; in children, 9-11 hours. The extended-release formulation provides a prolonged therapeutic effect masking shorter elimination.
Renal: ~90% unchanged; ~10% as deaminated metabolites; fecal <5%.
Approximately 90% of an oral dose is excreted renally, with 30% as unchanged amphetamine and the remainder as metabolites (including hippuric acid, benzoic acid, and hydroxylated derivatives). Fecal/biliary excretion accounts for <10%.
Category C
Category C
CNS Stimulant
CNS Stimulant